Glymenaki, M., Curio, S., Shrestha, S., Zhong, Q., Rushton, L., Barry, R., . . . Li, J. V. Roux-en-Y gastric bypass-associated fecal tyramine promotes colon cancer risk via increased DNA damage, cell proliferation, and inflammation. BMC.
Chicago Style (17th ed.) CitationGlymenaki, Maria, et al. Roux-en-Y Gastric Bypass-associated Fecal Tyramine Promotes Colon Cancer Risk via Increased DNA Damage, Cell Proliferation, and Inflammation. BMC.
MLA (9th ed.) CitationGlymenaki, Maria, et al. Roux-en-Y Gastric Bypass-associated Fecal Tyramine Promotes Colon Cancer Risk via Increased DNA Damage, Cell Proliferation, and Inflammation. BMC.
Warning: These citations may not always be 100% accurate.